Page 1

B braveheart bio September 2026 CORPORATE PRESENTATION Aiming to transform the standard of care for hypertrophic cardiomyopathy and related conditions . BHB - 1893 Next - generation oral cardiac myosin inhibitor in Phase 3 development Two indications Obstructive HCM ( OHCM ) and non - obstructive HCM ( nHCM ) Compelling Phase 2 data across efficacy , safety , and ease of use